AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11350703
Drug: Problem‐Solving Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem‐Solving Treatment for Primary Care (PST‐PC)
Trial: 11550739
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment conditions
Trial: 3370061
Drug: Torasemide 2.5
RxNorm normalized name: Torasemide 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide 2.5 mg
Trial: 3608350
Drug: Torasemide 5
RxNorm normalized name: Torasemide 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide 5 mg
Trial: 3608350
Drug: Torasemide 10
RxNorm normalized name: Torasemide 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide 10 mg
Trial: 3780838
Drug: Torasemide 20
RxNorm normalized name: Torasemide 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide 20 mg
Trial: 3370061
Drug: Torasemide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (all doses)
Trial: 22494567
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/day
Trial: 18675477
Drug: Granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony stimulating factor (G-CSF) administration
Trial: 18675477
Drug: G-CSF associated
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF associated to BMSC intracoronary infusion
Trial: 19004228
Drug: AD (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD (combined therapy)
Trial: 10421834
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) treatment in allergic asthmatic patients
Trial: 10421834
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) treatment in COPD patients
Trial: 27439370
Drug: Indacaterol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 150 μg
Trial: 7617857
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormonal replacement therapy (HRT)
Trial: 2213552
Drug: Sulindac, 200
RxNorm normalized name: Sulindac, 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac, 200 mg daily for 1 week
Trial: 20014253
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser treatment (635 nm, 17.5 mW, 3 times per week for 2 weeks)
Trial: 27590454
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser treatment
Trial: 14583848
Drug: L-glutamine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamine 30 g/day
Trial: 11054630
Drug: Dipyridamole (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (0.5 mg/kg body weight, intracoronary)
Trial: 8686403
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with biochemical modulators
Trial: 26636423
Drug: Exenatide +
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide + L-NMMA
Trial: 22348319
Drug: Breath-actuated nebulizer
RxNorm normalized name: beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breath-actuated nebulizer (BAN) delivering albuterol 2.5 mg or albuterol 2.5 mg plus ipratropium 0.25 mg
Trial: 22348319
Drug: Standard nebulizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nebulizer delivering albuterol 2.5 mg or albuterol plus ipratropium 0.5 mg
Trial: 17244215
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% once daily
Trial: 11382623
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% twice daily
Trial: 8165534
Drug: Gastrografin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrografin (100 ml administered through nasogastric tube)
Trial: 8355313
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with anti-pseudomonal third-generation cephalosporin (cefoperazone or ceftazidime)
Trial: 8355313
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with anti-pseudomonal third-generation cephalosporin (cefoperazone or ceftazidime) plus gentamicin
Trial: 2834488
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (CY 222)
Trial: 20698989
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT), treated 3 times per week for 12 weeks
Trial: 16647994
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (0.2 mg/kg body weight)
Trial: 16647994
Drug: Rectal diazepam
RxNorm normalized name: diazepam Rectal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diazepam (0.3 mg/kg body weight)
Trial: 1483156
Drug: Epinephrine injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine injection (unconditioned stimulus) for three or four days
Trial: 2255262
Drug: Calcium pidolate
RxNorm normalized name: calcium pidolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium pidolate (1 g elemental calcium)
Trial: 19243424
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate 800 mg
Trial: 11795850
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with FO (1 g EPA + DHA daily)
Trial: 11795850
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with ALNA (2 g daily)
Trial: 11026996
Drug: Oral sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulfasalazine (group 1)
Trial: 8892775
Drug: Bunazosin (alpha-blocker)
RxNorm normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin (alpha-blocker)
Trial: 6342407
Drug: Orthokeratology (OK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthokeratology (OK) treatment group
Trial: 2783678
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol
Trial: 22679525
Drug: Nitazoxanide (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (1,000 mg)
Trial: 19849767
Drug: AMC/DCBA throat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMC/DCBA throat lozenges (n = 155)
Trial: 2187445
Drug: Single-dose prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose prophylaxis with cefotiam and metronidazol
Trial: 31385333
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral health education (CE)
Trial: 21297191
Drug: 2‐year twice‐weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐year twice‐weekly weight training intervention
Trial: 20058059
Drug: Delayed Treatment
RxNorm normalized name: GRANULES, DELAYED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Treatment Control (DTC)
Trial: 19070356
Drug: Leukotriene receptor
RxNorm normalized name: Leukotriene receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene receptor antagonist
Trial: 7102584
Drug: equicaloric amount
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equicaloric amount of glucose solution
Trial: 7102584
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of water
Trial: 26020673
Drug: Protocol-based fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol-based fluid boluses (15 mL/kg)
Trial: 18469279
Drug: Lutein (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (12 mg/d)
Trial: 18469279
Drug: DHA (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (800 mg/d)
Trial: 23716765
Drug: Granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1 mg
Trial: 11299816
Drug: SK-1 administered
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK-1 administered intravenously at dosages of 2, 4, or 10 mg three times.
Trial: 9165140
Drug: Megestrol acetate,
RxNorm normalized name: megestrol acetate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megestrol acetate, 40 mg qid
Trial: 9165140
Drug: Cisapride, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 5 mg tid
Trial: 24286226
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy for 16 weeks
Trial: 24286226
Drug: Prophylactic regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic regimen nonacog alfa 100 IU kg(‐1) once weekly
Trial: 24286226
Drug: Prophylactic regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic regimen nonacog alfa 50 IU kg(‐1) twice weekly
Trial: 18703328
Drug: Pari Boy
RxNorm normalized name: Paris quadrifolia extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pari Boy device with 2.0 micromol/L capsaicin
Trial: 18703328
Drug: Maxin MA3
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxin MA3 device with 0.06 micromol/L capsaicin
Trial: 18703328
Drug: Maxin MA3
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxin MA3 device with 0.3 micromol/L capsaicin
Trial: 12796769
Drug: Enalapril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (mean dosage 14.6 mg, max 20 mg)
Trial: 10980076
Drug: Peer review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer review meetings with feedback on prescribing behaviour for asthma treatment.
Trial: 1391262
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of natural porcine surfactant (Curosurf)
Trial: 3755640
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg X kg‐1
Trial: 3755640
Drug: Succinylcholine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.0 mg X kg‐1
Trial: 3755640
Drug: Atracurium 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.75 mg X kg‐1
Trial: 19520905
Drug: Low-dose spiral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spiral computed tomography (LDCT)
Trial: 2662130
Drug: Terbutaline, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline, 5 mg
Trial: 2662130
Drug: Theophylline, 200
RxNorm normalized name: Theophylline, 200 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline, 200 mg
Trial: 31476413
Drug: Salmonella Typhi
RxNorm normalized name: Salmonella Typhi Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmonella Typhi vaccination (0.025 mg; Typhim Vi, Sanofi Pasteur, UK)
Trial: 27527240
Drug: Amitriptyline (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25, 50, 100 mg once daily at night for 1 week)
Trial: 23098325
Drug: Fluticasone/formoterol 250/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol 250/10 μg
Trial: 23098325
Drug: Fluticasone/formoterol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol (both doses)
Trial: 19797133
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antibiotic discontinuation strategy according to guidelines)
Trial: 22372513
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) initiated at 30 mg, titrated in 20 mg increments to a maximum of 70 mg over 4-5 weeks.
Trial: 27534056
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic therapy and Wobenzym
Trial: 12803576
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of plain-formulated aspirin (PFASA)
Trial: 1800302
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg tid for 4 weeks
Trial: 31504399
Drug: Low-dose rivaroxaban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rivaroxaban added to aspirin
Trial: 19249425
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (control)
Trial: 18597599
Drug: Amine fluoride/stannous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride/stannous fluoride (ASF) mouthrinse at 10 ml (ASF-10)
Trial: 18597599
Drug: Amine fluoride/stannous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride/stannous fluoride (ASF) mouthrinse at 20 ml (ASF-20)
Trial: 16267959
Drug: Amodiaquine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (30 mg/kg over three days, 10 mg/kg/day)
Trial: 16267959
Drug: Chloroquine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (30 mg/kg over three days, 10 mg/kg/day)
Trial: 12427293
Drug: Medication-free trial
RxNorm normalized name: benzoyl peroxide Medicated Pad [Triaz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-free trial after SSRI treatment
Trial: 12427293
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of SSRI treatment
Trial: 9457946
Drug: Washing, swim-down,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Washing, swim-down, refrigeration/heparin techniques
Trial: 7699828
Drug: Patient-Controlled Sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Sedation (PCS) - 1.5 mg bolus dose of midazolam
Trial: 23475568
Drug: Metformin (IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (IR and XR formulations)
Trial: 17275226
Drug: Black cohosh
RxNorm normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black cohosh (160 mg daily)
Trial: 17275226
Drug: Multibotanical including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multibotanical including black cohosh (200 mg daily)
Trial: 17275226
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen .625 mg, with or without medroxyprogesterone acetate 2.5mg daily
Trial: 11681821
Drug: Multivitamins with
RxNorm normalized name: MULTIVITAMINS WITH MINERALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamins with iron (MV with iron) administered daily for 3 months
Trial: 11681821
Drug: Noniron multivitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noniron multivitamins (MV without iron) administered daily for 3 months
Trial: 9226158
Drug: G-CSF (filgrastim)
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (filgrastim) 5 microg/kg/d subcutaneously
Trial: 11751732
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg sublingual nitroglycerin (NTG)
Trial: 3686222
Drug: Control (Diagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Diagnostic discography without enzyme injection)
Trial: 28930874
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of fish oil daily for 21 days
Trial: 22250190
Drug: 50‐mL roll‐on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50‐mL roll‐on dispenser
Trial: 16061828
Drug: Thyroxine suppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine suppressive treatment
Trial: 10879311
Drug: Triple-antibiotic ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-antibiotic ointment (polymyxin B-bacitracin-neomycin), applied twice daily for up to 14 days
Trial: 10879311
Drug: Simple gauze-type
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple gauze-type dressing, applied twice daily for up to 14 days
Trial: 8636300
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (100 mg, im, weekly) plus levonorgestrel (500 micrograms, orally, daily)
Trial: 1466089
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei preparation (BLP), 3 g/day
Trial: 29872280
Drug: Home-based program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based program + weekly class-style session (CS group, n=251)
Trial: 21178594
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg intravenous infusion)
Trial: 18450870
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation plus oral rehydration salts
Trial: 18450870
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salts alone (Control)
Trial: 7583751
Drug: Multimedia campaign
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimedia campaign regarding alcohol and other drug abuse
Trial: 2517626
Drug: 41% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 41% BCAA solution
Trial: 2517626
Drug: 23% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23% BCAA solution
Trial: 605356
Drug: 1-hyoscyamine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hyoscyamine (0.8 mg)
Trial: 27418685
Drug: PAH drug
RxNorm normalized name: PAH
DrugBank: Aminohippuric acid (DB00345)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAH drug treatment in inoperable CTEPH
Trial: 27418685
Drug: PAH drug
RxNorm normalized name: PAH
DrugBank: Aminohippuric acid (DB00345)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PAH drug treatment in operable CTEPH
Trial: 8941409
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2) and paclitaxel (135 mg/m2)
Trial: 8941409
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2) and cyclophosphamide (750 mg/m2)
Trial: 1780171
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of infected schoolchildren (Area S)
Trial: 1780171
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of individuals excreting >=800 epg (Area W)
Trial: 24852468
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound (HIFU) treatment with total fluence of 150-180 J/cm
Trial: 22513659
Drug: 0.6 g
RxNorm normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g per kg per day alanyl-glutamine
Trial: 12203176
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment program
Trial: 8964276
Drug: Carbamazepine 600
RxNorm normalized name: carbamazepine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 600 mg (CBZ 600)
Trial: 8964276
Drug: Lamotrigine 200
RxNorm normalized name: lamotrigine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 200 mg (LTG 200)
Trial: 31332820
Drug: Ilaprazole 30
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 30 mg
Trial: 31332820
Drug: Ilaprazole infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ilaprazole infusion
Trial: 30554571
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate therapy
Trial: 26729895
Drug: lenalidomide plus
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenalidomide plus low-dose dexamethasone (Rd)